BR112018001907A2 - uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica - Google Patents
uso de anticorpos anti-cd40 para o tratamento de nefrite lúpicaInfo
- Publication number
- BR112018001907A2 BR112018001907A2 BR112018001907A BR112018001907A BR112018001907A2 BR 112018001907 A2 BR112018001907 A2 BR 112018001907A2 BR 112018001907 A BR112018001907 A BR 112018001907A BR 112018001907 A BR112018001907 A BR 112018001907A BR 112018001907 A2 BR112018001907 A2 BR 112018001907A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- lupus nephritis
- antibodies
- therapeutic
- prevention
- Prior art date
Links
- 208000005777 Lupus Nephritis Diseases 0.000 title abstract 2
- 229940122551 CD40 antagonist Drugs 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212810P | 2015-09-01 | 2015-09-01 | |
| US201562257336P | 2015-11-19 | 2015-11-19 | |
| US201662287587P | 2016-01-27 | 2016-01-27 | |
| PCT/US2016/049558 WO2017040566A1 (en) | 2015-09-01 | 2016-08-31 | Use of anti-cd40 antibodies for treatment of lupus nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018001907A2 true BR112018001907A2 (pt) | 2018-09-25 |
Family
ID=56896810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018001907A BR112018001907A2 (pt) | 2015-09-01 | 2016-08-31 | uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20170058038A1 (enExample) |
| EP (1) | EP3344655B1 (enExample) |
| JP (2) | JP2018529661A (enExample) |
| KR (1) | KR20180039172A (enExample) |
| CN (1) | CN107922501A (enExample) |
| AU (1) | AU2016317028B2 (enExample) |
| BR (1) | BR112018001907A2 (enExample) |
| CA (1) | CA2993996A1 (enExample) |
| CL (1) | CL2018000317A1 (enExample) |
| DK (1) | DK3344655T5 (enExample) |
| ES (1) | ES2969968T3 (enExample) |
| HU (1) | HUE063528T2 (enExample) |
| MX (1) | MX390653B (enExample) |
| PH (1) | PH12018500445B1 (enExample) |
| PL (1) | PL3344655T3 (enExample) |
| WO (1) | WO2017040566A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110719915A (zh) * | 2017-05-25 | 2020-01-21 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
| BR112020024078A2 (pt) * | 2018-06-29 | 2021-02-17 | Boehringer Ingelheim International Gmbh | anticorpos anti-cd40 para uso no tratamento de doença autoimune |
| CN112839961B (zh) * | 2018-11-30 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 一种cd40抗体药物组合物及其用途 |
| SI4284512T1 (sl) | 2021-01-28 | 2025-06-30 | Regeneron Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje sindroma sproščanja citokinov |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ATE161192T1 (de) | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| RU2006141632A (ru) * | 2004-04-27 | 2008-06-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) | Антагонистические моноклональные анти-cd40-антитела и способы их применения |
| RU2407544C2 (ru) * | 2005-05-26 | 2010-12-27 | Сиэтл Дженетикс, Инк. | Гуманизированные анти-cd40-антитела и способы их применения |
| BRPI0710826A2 (pt) * | 2006-04-21 | 2011-08-23 | Novartis Ag | composições farmacêuticas de anticorpo anti-cd40 antagonista |
| SG183947A1 (en) * | 2010-03-31 | 2012-10-30 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
| EP2702078B1 (en) * | 2011-04-29 | 2018-11-07 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
-
2016
- 2016-08-31 EP EP16763663.8A patent/EP3344655B1/en active Active
- 2016-08-31 US US15/252,308 patent/US20170058038A1/en not_active Abandoned
- 2016-08-31 CA CA2993996A patent/CA2993996A1/en active Pending
- 2016-08-31 DK DK16763663.8T patent/DK3344655T5/da active
- 2016-08-31 CN CN201680050230.6A patent/CN107922501A/zh active Pending
- 2016-08-31 WO PCT/US2016/049558 patent/WO2017040566A1/en not_active Ceased
- 2016-08-31 JP JP2018511144A patent/JP2018529661A/ja active Pending
- 2016-08-31 HU HUE16763663A patent/HUE063528T2/hu unknown
- 2016-08-31 PH PH1/2018/500445A patent/PH12018500445B1/en unknown
- 2016-08-31 MX MX2018002447A patent/MX390653B/es unknown
- 2016-08-31 KR KR1020187009176A patent/KR20180039172A/ko not_active Ceased
- 2016-08-31 AU AU2016317028A patent/AU2016317028B2/en not_active Ceased
- 2016-08-31 BR BR112018001907A patent/BR112018001907A2/pt not_active Application Discontinuation
- 2016-08-31 ES ES16763663T patent/ES2969968T3/es active Active
- 2016-08-31 PL PL16763663.8T patent/PL3344655T3/pl unknown
-
2018
- 2018-02-05 CL CL2018000317A patent/CL2018000317A1/es unknown
- 2018-07-18 US US16/038,536 patent/US20190177420A1/en not_active Abandoned
-
2021
- 2021-08-20 JP JP2021134828A patent/JP2021185169A/ja active Pending
-
2022
- 2022-10-07 US US17/962,099 patent/US20230265203A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3344655T3 (pl) | 2024-02-19 |
| EP3344655A1 (en) | 2018-07-11 |
| US20230265203A1 (en) | 2023-08-24 |
| US20190177420A1 (en) | 2019-06-13 |
| MX390653B (es) | 2025-03-21 |
| JP2021185169A (ja) | 2021-12-09 |
| JP2018529661A (ja) | 2018-10-11 |
| MX2018002447A (es) | 2018-06-15 |
| PH12018500445B1 (en) | 2022-08-10 |
| HUE063528T2 (hu) | 2024-01-28 |
| EP3344655B1 (en) | 2023-07-26 |
| WO2017040566A1 (en) | 2017-03-09 |
| US20170058038A1 (en) | 2017-03-02 |
| DK3344655T3 (da) | 2023-10-09 |
| KR20180039172A (ko) | 2018-04-17 |
| ES2969968T3 (es) | 2024-05-23 |
| AU2016317028A1 (en) | 2018-02-22 |
| CA2993996A1 (en) | 2017-03-09 |
| PH12018500445A1 (en) | 2018-09-10 |
| CN107922501A (zh) | 2018-04-17 |
| DK3344655T5 (da) | 2024-10-07 |
| AU2016317028B2 (en) | 2021-09-09 |
| CL2018000317A1 (es) | 2018-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018001907A2 (pt) | uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica | |
| HUE067888T2 (hu) | Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával | |
| BR112016022658A2 (pt) | anticorpos anti-ox40 e métodos de uso | |
| BR112017017927A2 (pt) | receptores quiméricos de antígenos anti-dll3 e métodos de uso | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
| BR112017000664A2 (pt) | anticorpo anti-pd-1 e seu uso | |
| BR112018014016A2 (pt) | combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer | |
| PH12016502167A1 (en) | Hdl theraphy markers | |
| BR112017009297A2 (pt) | anticorpos antifator de complemento c1q humanizados e usos dos mesmos | |
| BR112017005266A2 (pt) | inibidores de mk2 e uso dos mesmos | |
| LT3594238T (lt) | Antikūno kompozicijos, skirtos navikų gydymui | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| CL2020003348A1 (es) | Anticuerpos anti–cd40 para su uso en el tratamiento de enfermedades autoinmunes | |
| BR112017007414A2 (pt) | combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| BR112016019176A2 (pt) | anticorpos il-21 | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| BR112019023742A2 (pt) | anticorpos anti-trkb | |
| BR112017009000A2 (pt) | apilimod para uso no tratamento de melanoma | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
| EA201691896A1 (ru) | Соединения и способы их применения | |
| EA201691452A1 (ru) | Композиции для применения в лечении аллергических состояний | |
| EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
| KR101912544B9 (ko) | 어큐빈을 포함하는 신경정신 질환의 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |